Am. J. Respir. Crit. Care Med., Vol 149, No. 3, 03 1994, 815-817.
Oral desensitization to rifampin and ethambutol in mycobacterial disease
J Matz, LC Borish, JM Routes and LJ Rosenwasser
Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, Denver, CO 80206.
The incidence of disease caused by Mycobacterium tuberculosis (including
drug-resistant strains) and M. avium complex (MAC) is increasing.
Hypersensitivity reactions to antimycobacterial agents are relatively
uncommon, but when they occur they may result in cessation of therapeutic
medications. We report our experience with rapid oral desensitization to
ethambutol and rifampin in a group of 10 patients with mycobacterial
disease who had experienced cutaneous hypersensitivity reactions to these
drugs. An adaptation of the rapid oral desensitization protocol for
penicillin was used, with the dosing intervals increased to account for the
different kinetics of these drugs. Adverse reactions were few and easily
treated without necessitating cessation of therapy. We conclude that oral
desensitization to rifampin and ethambutol by our protocol is safe and
effective, allowing these patients to proceed with an optimal
antimycobacterial regimen.